By Suvarna Bhatt
San Francisco, March 2 (BioSpace) – Spanish companies, Biotherapix and Digna Biotech announced they have entered into an agreement for the development of products for the treatment of pulmonary fibrosis.
Biotherapix’s M3 protein and Digna Biotech’s P17 peptide are at the center for the agreement. Both compounds are thought to be good candidates for treating pulmonary fibrosis.
Biotherapix and Digna Biotech will invest 3 million euros over the next four years to fund product development.
Contact Suvarna Bhatt at sbhatt@biospace.com
